Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LPCN

Lipocine Inc

Dec 08 • 04:00PM ET

2.56

Dollar change -0.04
Percentage change -1.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.14	Insider Own	2.77%	Shs Outstand	5.21M	Perf Week	-2.50%
Market Cap	13.64M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	0.00%	Shs Float	5.17M	Perf Month	2.98%
Income	-16.30M	PEG	-	EPS next Q	-0.47	Inst Own	9.48%	Short Float / Ratio	2.98% / 9.25	Perf Quarter	-31.62%
Sales	0.05M	P/S	272.83	EPS this Y	-35.29%	Inst Trans	-65.34%	Short Interest	0.15M	Perf Half Y	-40.37%
Book/sh	4.23	P/B	0.61	EPS next Y	44.15%	ROA	-50.80%	Target Price	33.00	Perf Year	-63.33%
Cash/sh	4.48	P/C	0.57	EPS next 5Y	-	ROE	-54.21%	52W Range	2.31 - 10.33	Perf YTD	-62.08%
Dividend	-	P/FCF	-	EPS past 5Y	35.02%	ROI	-72.50%	52W High	-75.18%	Beta	1.07
Dividend %	-	Quick Ratio	10.98	Sales past 5Y	-51.67%	Gross Margin	57.75%	52W Low	11.00%	ATR	0.17
Employees	17	Current Ratio	10.98	Sales Q/Q	-	Oper. Margin	-26871.14%	RSI (14)	48.74	Volatility	3.45% 7.32%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-174.67%	Profit Margin	-29641.28%	Rel Volume	0.40	Prev Close	2.60
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 08 BMO	Payout	-	Avg Volume	16.66K	Price	2.56
Recom	1.00	SMA20	-0.00%	SMA50	-2.36%	SMA200	-39.89%	Volume	6,601	Change	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-24-21	Initiated	Cantor Fitzgerald	Overweight	$3
Dec-10-20	Upgrade	Ladenburg Thalmann	Neutral → Buy	$3
Jan-12-18	Reiterated	H.C. Wainwright	Buy	$10 → $3
Jan-11-18	Downgrade	Canaccord Genuity	Buy → Hold	$11 → $2
Dec-08-17	Resumed	H.C. Wainwright	Buy	$10
Oct-07-16	Initiated	H.C. Wainwright	Buy	$25
Jul-22-15	Initiated	ROTH Capital	Buy	$36
Jun-23-15	Initiated	Canaccord Genuity	Buy	$15

Nov-13-23 02:45PM	Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting 2023 (PR Newswire) +11.20%
Nov-08-23 08:17AM	Lipocine: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 (PR Newswire)
Nov-01-23 08:00AM	Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023 (PR Newswire)
Oct-26-23 08:00AM	Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression (PR Newswire)
07:00PM	Loading…
Oct-23-23 07:00PM	Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference (PR Newswire)
Sep-19-23 04:05PM	Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
Aug-16-23 06:02AM	LPCN: Trial Results Improve Outlook (Zacks)
Aug-10-23 08:09AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 (PR Newswire)
Jul-31-23 06:13AM	LPCN: 1148 Shows Muscle Loss Reversal (Zacks)
Jul-27-23 06:30AM	LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis (PR Newswire) +18.60%
Jun-14-23 08:00AM	Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference (PR Newswire)
Jun-07-23 08:00AM	Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 (PR Newswire)
May-19-23 09:14AM	LPCN: 1154 Results Illuminate Accelerated Pathway (Zacks Small Cap Research)
07:00AM	Loading…
May-16-23 07:00AM	Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression (PR Newswire) -17.72%
May-11-23 06:23AM	Lipocine: Q1 Earnings Snapshot (AP Finance) +7.30%
06:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 (PR Newswire)
Apr-03-23 08:00AM	First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 (PR Newswire)
Mar-16-23 06:00AM	LPCN: 2022 Operational & Financial Update (Zacks Small Cap Research) +9.55%
Mar-10-23 08:30AM	Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock (PR Newswire) -26.79%
08:30AM	Lipocine Announces Financial Results for the Year Ended December 31, 2022 (PR Newswire)
Jan-16-23 08:06AM	Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? (Simply Wall St.)
Jan-05-23 08:00AM	Lipocine to Present at Biotech Showcase (PR Newswire)
Dec-19-22 08:00AM	Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis (PR Newswire) +5.62%
Nov-30-22 04:28AM	LPCN: Focus on CNS Disorders (Zacks Small Cap Research)
Nov-09-22 08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022 (PR Newswire) -5.98%
Nov-03-22 08:00AM	Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline (PR Newswire)
Oct-11-22 08:00AM	Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference (PR Newswire)
Sep-27-22 01:21PM	Lipocine to Participate in the Cantor Neurology & Psychiatric Conference (PR Newswire) -11.85%
11:39AM	Loading…
Sep-26-22 11:39AM	Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets (Benzinga) -10.41%
08:00AM	Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders (PR Newswire)
Sep-22-22 04:10PM	Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference (PR Newswire)
Sep-15-22 08:00AM	Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) (PR Newswire) +5.69%
Aug-10-22 06:04AM	LPCN: TLANDO Launched (Zacks Small Cap Research)
Aug-09-22 06:41AM	Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
Aug-08-22 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 (PR Newswire) -11.09%
Jul-11-22 08:00AM	FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment (PR Newswire)
Jun-14-22 08:00AM	LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS (PR Newswire)
Jun-06-22 04:00PM	LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE (PR Newswire)
May-20-22 07:12AM	LPCN: OLE Results (Zacks Small Cap Research)
May-12-22 10:55AM	Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients (Benzinga)
08:00AM	Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results (PR Newswire)
May-10-22 11:30AM	LPCN: First Quarter 2022 Financial and Operational Results (Zacks Small Cap Research)
May-09-22 08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022 (PR Newswire)
May-04-22 06:34AM	Shareholders in Lipocine (NASDAQ:LPCN) are in the red if they invested five years ago (Simply Wall St.)
Apr-11-22 08:00AM	LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS (PR Newswire)
Mar-29-22 07:34PM	7 Undervalued Penny Stocks With Major Upside (InvestorPlace) -20.33%
07:05AM	LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO (PR Newswire)
Mar-11-22 04:26AM	LPCN: 2021 Results (Zacks Small Cap Research)
Mar-09-22 08:00AM	Lipocine Announces Financial Results for the Year Ended December 31, 2021 (PR Newswire) +6.38%
Mar-01-22 08:00AM	Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH (PR Newswire)
Feb-25-22 07:42AM	Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Feb-03-22 08:00AM	LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® (PR Newswire)
Jan-27-22 08:00AM	Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® (PR Newswire)
Jan-05-22 08:00AM	Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference (PR Newswire)
Dec-22-21 08:00AM	LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS (PR Newswire)
Nov-19-21 09:04AM	5 Penny Stocks Insiders Are Buying (Benzinga) +7.34%
Nov-11-21 10:00AM	LPCN: Third Quarter Update (Zacks Small Cap Research)
Nov-10-21 08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021 (PR Newswire)
Nov-08-21 08:18AM	LPCN: Antares Agreement & NASH Fast Track Change the Calculus (Zacks Small Cap Research) +7.14%
Nov-04-21 08:00AM	Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH (PR Newswire) +6.31%
Nov-01-21 08:00AM	Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 (PR Newswire)
Oct-19-21 07:00AM	18 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Oct-18-21 12:15PM	Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US (Benzinga)
07:00AM	Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO® (PR Newswire)
Oct-05-21 08:00AM	Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference (PR Newswire)
Sep-28-21 08:00AM	Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO® (PR Newswire)
Sep-20-21 08:00AM	Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference (PR Newswire)
Sep-01-21 08:00AM	Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-31-21 05:43AM	LPCN: Liver Biopsy Results (Zacks Small Cap Research)
Aug-25-21 06:30AM	Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study (PR Newswire)
Aug-09-21 07:12AM	LPCN: New Candidate in Postpartum Depression (Zacks Small Cap Research) +6.62%
Aug-05-21 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021 (PR Newswire)
Jul-15-21 09:00AM	Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine (GlobeNewswire)
Jul-14-21 04:00PM	Lipocine Announces Settlement With Clarus Therapeutics (PR Newswire)
Jul-06-21 08:00AM	Lipocine To Present At The Ladenburg Thalmann Healthcare Conference (PR Newswire)
Jun-23-21 08:00AM	Lipocine Announces Presentations at The International Liver Congress 2021 Digital Event (PR Newswire)
Jun-16-21 08:00AM	Lipocine To Present At The Raymond James Human Health Innovation Conference (PR Newswire)
Jun-14-21 08:00AM	FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study (PR Newswire)
Jun-07-21 08:00AM	Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference (PR Newswire)
May-27-21 05:31AM	LPCN: Summary Judgment Spurns Lipocine (Zacks Small Cap Research)
May-26-21 12:44PM	Clarus Therapeutics Wins Jatenzo Patent Infringement Case Brought By Lipocine (Benzinga) -11.68%
08:00AM	Summary Judgment Ruling in Patent Infringement Lawsuit (PR Newswire)
May-25-21 08:32PM	Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment (PR Newswire)
May-24-21 05:40AM	LPCN: 1Q:21 Results (Zacks Small Cap Research)
May-19-21 05:04AM	Market Sentiment Around Loss-Making Lipocine Inc. (NASDAQ:LPCN) (Simply Wall St.)
May-06-21 08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 (PR Newswire)
Mar-22-21 08:41AM	LPCN: Forging Tlandos Path Forward (Zacks Small Cap Research)
Mar-11-21 08:00AM	Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference (PR Newswire) +12.08%
08:00AM	Lipocine Announces Financial Results For The Year Ended December 31, 2020 (PR Newswire)
Mar-04-21 08:00AM	Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis (PR Newswire)
Mar-03-21 08:00AM	Lipocine Announces Presentations on TLANDO at ENDO 2021 Conference (PR Newswire) -7.74%
Feb-26-21 08:00AM	Lipocine to Present at Two Upcoming Investor Conferences (PR Newswire)
Jan-28-21 04:00PM	Lipocine Closes Underwritten Public Offering Of Common Stock (PR Newswire) -6.22%
Jan-26-21 09:00AM	Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock (PR Newswire) -10.00%
Jan-25-21 04:00PM	Lipocine Announces Launch Of Public Offering Of Common Stock (PR Newswire)
Jan-19-21 01:45PM	LPCN: Lipocines LiFT Results: A Comparison with Peers (Zacks Small Cap Research) +8.64%
Jan-14-21 08:11AM	LPCN: LiFT: Twelve-week Topline Touts Statistical Significance (Zacks Small Cap Research) +7.84%
08:00AM	Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications (PR Newswire)

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Mahesh V.	CEO and President	May 25	Buy	5.03	8,706	43,791	107,418	May 25 03:10 PM
Patel Mahesh V.	CEO and President	Mar 24	Buy	0.32	150,000	48,000	1,678,090	Mar 24 05:28 PM
Ono Richard Dana	Director	Mar 20	Buy	0.34	4,000	1,360	14,125	Mar 20 06:51 PM
Patel Mahesh V.	CEO and President	Mar 17	Buy	0.33	50,000	16,500	1,528,090	Mar 17 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LPCN

Lipocine Inc

Upgrade your FINVIZ experience